Recombinant antithrombin produced by baby hamster kidney (BHK) or Chinese hamster ovary (CHO) cells was separated into two fractions, containing comparable amounts of protein, by affinity chromatography on matrix-linked heparin. Fluorescence titrations showed that the more tightly binding fraction had a heparin affinity similar to that of plasma antithrombin (Kd 20 nM), whereas the affinity of the more weakly binding fraction was nearly 10-fold lower (Kd 175 nM). Analyses of the heparin-catalysed rate of inhibition of thrombin further showed that the fractions differed only in their affinity for heparin and not in the intrinsic rate constant of either the uncatalysed or the heparin-catalysed inactivation of thrombin. The recombinant antithrombin fraction with lower heparin affinity migrated more slowly than both the fraction with higher affinity and plasma antithrombin in SDS/PAGE under reducing conditions, consistent with a slightly higher apparent relative molecular mass. This apparent size difference was abolished by the enzymic removal of the carbohydrate side chains from the proteins. Such removal also increased the heparin affinity of the weakly binding fraction, so that it eluted from matrix-linked heparin at a similar position to the deglycosylated tightly binding fraction or plasma antithrombin. Analyses of N-linked carbohydrate side chains showed that the weakly binding fraction from CHO cells had a higher proportion of tetra-antennary and a lower proportion of biantennary oligosaccharides than the tightly binding fraction. We conclude that the recombinant antithrombin produced by the two cell lines is heterogeneously glycosylated and that the increased carbohydrate content of a large proporti6n of the molecules results in a substantial decrease in the affinity of these molecules for heparin. These findings are of particular relevance for studies aimed at characterizing the heparin-binding site of recombinant antithrombin by site-directed mutagenesis.
Recombinant antithrombin produced by baby hamster kidney (BHK) or Chinese hamster ovary (CHO) cells was separated into two fractions, containing comparable amounts of protein, by affinity chromatography on matrix-linked heparin. Fluorescence titrations showed that the more tightly binding fraction had a heparin affinity similar to that of plasma antithrombin (Kd 20 nM), whereas the affinity of the more weakly binding fraction was nearly 10-fold lower (Kd 175 nM). Analyses of the heparin-catalysed rate of inhibition of thrombin further showed that the fractions differed only in their affinity for heparin and not in the intrinsic rate constant of either the uncatalysed or the heparin-catalysed inactivation of thrombin. The recombinant antithrombin fraction with lower heparin affinity migrated more slowly than both the fraction with higher affinity and plasma antithrombin in SDS/PAGE under reducing conditions, consistent with a slightly higher apparent relative molecular mass. This apparent size difference was abolished by the enzymic removal of the carbohydrate side chains from the proteins. Such removal also increased the heparin affinity of the weakly binding fraction, so that it eluted from matrix-linked heparin at a similar position to the deglycosylated tightly binding fraction or plasma antithrombin. Analyses of N-linked carbohydrate side chains showed that the weakly binding fraction from CHO cells had a higher proportion of tetra-antennary and a lower proportion of biantennary oligosaccharides than the tightly binding fraction. We conclude that the recombinant antithrombin produced by the two cell lines is heterogeneously glycosylated and that the increased carbohydrate content of a large proporti6n of the molecules results in a substantial decrease in the affinity of these molecules for heparin. These findings are of particular relevance for studies aimed at characterizing the heparin-binding site of recombinant antithrombin by site-directed mutagenesis.
INTRODUCTION
Antithrombin is a plasma glycoprotein that inhibits most proteinases of the coagulation cascade and thus plays a major role in the regulation of blood clotting (for reviews, see Bj6rk & Danielsson, 1986; Bj6rk et al., 1989b; Olson & Bj6rk, 1992) . The sulphated polysaccharide heparin dramatically accelerates this inhibition, thereby acting as an effective anticoagulant. The accelerating ability of heparin is dependent on the tight binding (Kd -20 nM) of a unique pentasaccharide region, occurring in only about one-third of the heparin chains, to antithrombin at a site which has not yet been conclusively identified. This binding induces a conformational change in antithrombin which is sufficient to cause the inhibitor to react more rapidly with some clotting enzymes, e.g. factor Xa. However, the inhibition of other clotting proteinases, such as thrombin, requires the additional binding of the enzyme to the same heparin chain. Heparin thus appears to accelerate the inhibition of these proteinases primarily by bringing together inhibitor and enzyme on the polysaccharide surface.
The amino acid and cDNA sequences of antithrombin, as well as the intron structure of the antithrombin gene, have been determined (Petersen et al., 1979; Bock et al., 1982; Prochownik et al., 1985; Bock et al., 1988) , and the protein has been expressed in yeast, insect cells and mammalian cell lines (Zettlmeissl et al., 1987 (Zettlmeissl et al., , 1988 (Zettlmeissl et al., , 1989 Stephens et al., 1987; Wasley et al., 1987; Br6ker et al., 1987; Gillespie et al., 1991) . It has thus become feasible to design studies, using site-directed mutagenesis, of the structure and localization of the heparinbinding site of antithrombin. The results of the present work demonstrate a potential complication to such studies, namely that variations in the glycosylation state of antithrombin expressed by mammalian cell lines markedly affect the affinity of the inhibitor for heparin. These variations have to be taken into account in evaluations of the effect of different amino acid substitutions on heparin affinity.
MATERIALS AND METHODS Proteins
Antithrombin was purified from expired citrated human plasma by affinity chromatography on immobilized heparin (Miller-Andersson et al., 1974; Olson & Shore, 1982; Olson, 1988) . The minor antithrombin fraction ('antithrombin /1'), with a lower carbohydrate content and a somewhat higher heparin affinity than the major form of the protein (Carlson & Atencio, 1982; Peterson & Blackburn, 1985) , was excluded from the pool used. Recombinant human antithrombin was expressed in baby hamster kidney (BHK) cells or Chinese hamster ovary (CHO) cells, as described previously (Zettlmeissl et al., 1987 (Zettlmeissl et al., , 1988 (Zettlmeissl et al., , 1989 . The protein was isolated from the medium by heparin affinity chromatography with stepwise elution, followed by ammonium sulphate precipitation (Zettlmeissl et al., 1989) .
The recombinant antithrombin was further fractionated by gradient elution from matrix-linked heparin. About 5 mg of protein was applied to a column (1 cm x 8 cm) of heparinAbbreviations used: BHK, baby hamster kidney; CHO, Chinese hamster ovary; HPAE-PAD, high-pH anion-exchange chromatography with pulsed amperometric detection.
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Sepharose (Pharmacia LKB Biotechnology, Uppsala, Sweden), which was eluted at a flow rate of 0.3 ml/min with a linear gradient (total volume 100 ml) from 0.02 M-sodium phosphate/ 0.1 M-NaCl, pH 7.4, to the same buffer containing 2 M-NaCl. Fractions of 1 ml were collected. The protein content of the fractions was analysed by tryptophan fluorescence in an SLM 4800S spectrofluorimeter (SLM-Aminco, Urbana, IL, U.S.A.) with excitation and emission wavelengths of 280 and 340 nm respectively. Appropriate fractions were pooled and concentrated by ultrafiltration.
Concentrations of both plasma and recombinant antithrombin were obtained by absorption measurements at 280 nm with the use of a specific absorption coefficient of 0.65 litres * g-1 cm-' and an Mr of 58000 (Nordenman et al., 1977) , unless otherwise indicated.
Human a-thrombin (> 99 % a-form) was generously donated by Dr. John Fenton, New York State Department of Public Health. Stock concentrations were determined by active-site titrations with 4-methylumbelliferyl-p-guanidinobenzoate (Jameson et al., 1973) . The enzyme was found to be > 90 % active in these analyses .
Heparin
Heparin with a narrow Mr distribution and with high affinity for antithrombin was isolated by two successive gel chromatographies followed by affinity chromatography on immobilized antithrombin, as described previously (Hook et al., 1976; Olson & Shore, 1982 , 1986 Olson, 1988) . The high-affinity heparin fraction used had an average Mr of 7900 (Olson, 1988) . Its concentration was determined as antithrombin-binding sites by stoichiometric titrations, monitored by fluorescence (see below), of antithrombin at a concentration about 100-fold higher than the dissociation constant (Olson, 1988) . This high-affinity heparin fraction was used throughout, except in the studies involving heparin affinity chromatography.
Protein analyses
Amino acid analyses were carried out on an LKB 4151 Alpha Plus amino acid analyser (Pharmacia LKB) after hydrolysis of the samples in 6 M-HCI at 110°C for 24 and 72 h. N-Terminal sequences were analysed as described previously (Bjork et al., 1989a) .
Immunodiffusion was done in a 1 % agarose gel in 0.02 Msodium phosphate/0.1 M-NaCl, pH 7.4 (Nordenman et al., 1977) with a commercial antiserum against plasma antithrombin (Dakopatts, Glostrup, Denmark).
Heparin binding
Titrations of antithrombin with high-affinity heparin were monitored in the SLM spectrofluorimeter by the increase in tryptophan fluorescence accompanying the interaction Danielsson et al., 1986) . The analyses were carried out at 25°C by successive additions of heparin to a cuvette containing antithrombin (100-500 nM) in 0.02 M-sodium phosphate/0.1 M-NaCl/100 4M-EDTA/0.1 % (w/v)-poly(ethylene glycol), pH 7.4. The excitation and emission wavelengths were 280 and 340 nm respectively, and the corresponding bandwidths were 4 and 8 nm. Apparent stoichiometries and dissociation constants were evaluated by non-linear least-squares regression analysis of the titration curves (Nordenman & Bj6rk, 1978) .
Thrombin inactivation
The heparin-catalysed rate of inactivation of thrombin by antithrombin was measured at.. 25°C in 0.02 M-sodium phosphate/0. 1 M-NaCl/100 4uM-EDTA/0. 1 % (w/v) poly(ethylene glycol)/0.1 % (w/v) BSA, pH 7.4. Thrombin (final concentration 0.5-1 nM) was added to a mixture of antithrombin and heparin (final concentrations 5-200 nm and 1 nm respectively) to give a total volume of 50 #1 in an acrylic fluorescence cuvette.
Identical samples at each antithrombin concentration were allowed to react for various times, after which the reactions were quenched by addition of 1 ml of a 50 4UM solution of the fluorogenic thrombin substrate N-p-tosyl-glycyl-L-prolyl-Larginyl 7-amido-4-methylcoumarin (Sigma, St. Louis, MO, U.S.A.), containing 50 jtg of polybrene/ml. Residual thrombin activity was obtained from the initial rate of substrate hydrolysis (< 1 % of substrate consumption), measured in a Perkin-Elmer 650-10 S (Perkin-Elmer, Norwalk, CN, U.S.A.) or in the SLM spectrofluorimeter with excitation and emission wavelengths of 380 and 440 nm respectively. Before these studies, possibly contaminating heparin in the antithrombin preparations was removed by ion-exchange chromatography on a Mono Q column (Pharmacia LKB). The antithrombin concentrations of the resulting samples were determined by titrations of 50 nM-thrombin with increasing amounts of antithrombin, monitored by measurements of residual thrombin activity with the fluorogenic substrate after incubation at 25°C for 16 h.
Analyses of deglycosylated protein
Antithrombin was deglycosylated with endoglycosidase F/N-glycosidase F (Boehringer, Mannheim, Germany) under denaturing conditions by addition of 0.05 or 2.5 units of enzyme to 70-120 ,ug of antithrombin (0.7-1.2 mg/ml) in 0.04 M-sodium phosphate/0.1 M-NaCl/2 mM-EDTA/l0 mM-flmercaptoethanol/0.2 % (w/v) Triton X-100/0.2 % (w/v) SDS, pH 6.5. After incubation for 24 or 48 h at 37°C, the samples were analysed by SDS/PAGE under reducing conditions with the use of a Tris buffer system (Laemmli, 1970) .
Oligosaccharides were removed from antithrombin under nondenaturing conditions by addition of 2.5 units ofendoglycosidase F/N-glycosidase F to 200 ,ug of antithrombin (0.65-0.85 mg/ml) in 0.04 M-sodium phosphate/0. 1 M-NaCl/2 mM-EDTA, pH 6.5. The samples were incubated for 24 h at 37°C and were then analysed by SDS/PAGE under reducing conditions. Amounts of 160 ,ug of the digested samples were also applied to an analytical heparin-Sepharose (Pharmacia LKB) column (0.5 cm x 5.5 cm), which was eluted at a flow rate of 0.1 ml/min with a linear gradient (total volume 20 ml) from 0.02 M-sodium phosphate/ 0.1 M-NaCl, pH 7.4, to the same buffer containing 2 M-NaCl with the use of the Pharmacia LKB h.p.l.c. system. The protein concentration of the effluent was monitored by continuous measurements of absorbance at 280 nm. Controls of undigested antithrombin were analysed in the same manner.
Endoglycosidase H (Boehringer) digestion of antithrombin under non-denaturing conditions was done for 24 h at 37°C with 0.05 unit of enzyme and 150-170 /tg of antithrombin (0.56-0.61 mg/ml) in 0.02 M-sodium phosphate/0.1 M-NaCl/I00 /LM-EDTA, pH 5.6. The samples were analysed by SDS/PAGE under reducing conditions and by analytical affinity chromatography on immobilized heparin, as described above.
Antithrombin was digested with Vibrio cholerae neuraminidase (Behringwerke, Marburg, Germany) for 20 h at 37°C in 0.05 MMes/NaOH/1 mM-CaCl2/0.2 % (w/v) poly(ethylene glycol), pH 6.5. The antithrombin concentration was 0.4-0.8 mg/ml, and the amount of enzyme was 0.5 unit/250,tg of protein. The digested samples were analysed by PAGE under native conditions (Davis, 1964) and by analytical affinity chromatography on immobilized heparin.
Analyses of N-linked oligosaccharides
For analyses of the relative proportions of different N-linked
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Heparin affinity of recombinant antithrombin oligosaccharides in recombinant antithrombin fractions I and II, the proteins were reduced and S-carboxamidomethylated (Zetthmeissl et al., 1989) , and then digested with trypsin (sequencing grade; Boehringer) at an enzyme/protein ratio of 1:20 (w/w) for 6-12 h at 37°C in 50 mM-Tris/HCl, pH 8.1. Peptides were separated by reverse-phase h.p.l.c. on a C18 column (Vydac, Hesperia, CA, U.S.A.). and glycopeptides were detected by carbohydrate compositional analyses essentially as described previously (Zettlmeissl et al., 1989) . Total N-linked oligosaccharides were liberated from the pooled glycopeptides by digestion of 5-10 nmol of glycopeptides in 0.5 ml of 50 mmsodium phosphate/10 mM-EDTA/0.02 % (w/v) NaN3, pH 7.5, with 5 units of N-glycosidase F (Boehringer) for 12 h at 37 'C. The released oligosaccharides were recovered in the first 10 ml of the eluate from a reverse-phase h.p.l.c. on a C18 column. Quantitative liberation of the oligosaccharides was indicated by the failure to detect any carbohydrate in the residual peptide material and by the fact that, after neuraminidase treatment of this material, no radiolabel could be introduced by a resialylation attempt with CMP-[14C]NeuAc and Galfll-4GlcNac-R a2-6 sialyltransferse (Conradt et al., 1987) . NeuAc was enzymically released from the cligosaccharide pool by treatment of 1-5 ,ug of oligosaccharides with 0.01 unit of Vibrio cholerae neuraminidase (Calbiochem, San Diego, CA, U.S.A.) in 100 #l of 0.0125 Msodium acetate/1.25 mM-CaCl2/0.005 % (w/v) NaN3, pH 5.0, for 1 h at 37 'C. Liberated NeuAc and desialylated oligosaccharides in the treated material were then analysed by highpH anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD) (Hardy & Townsend, 1988; Nimtz et al., 1990; Conradt et al., 1991; . Individual oligosaccharides were identified by comparison with similarly desialylated reference oligosaccharides that had previously been characterized by methylation analyses, fast-atom bombardment mass spectroscopy and 'H-n.m.r. (Conradt et al., 1987; Zettlmeissl et al., 1989; Nimtz et al., 1990; . NeuAc was also analysed by HPAE-PAD after being released from the undigested glycoproteins by acid hydrolysis (Hermentin & Seidat, 1991) .
RESULTS

Fractionation of recombinant antithrombin
Fractionation of antithrombin produced by BHK cells by affinity chromatography on matrix-linked heparin with the use of gradient elution resulted in two major peaks, designated I and II (Fig. 1) . Fraction II, comprising -60 % of the protein, eluted at -0.9 M-NaCl, i.e. similar to a plasma antithrombin control, whereas fraction I, comprising -40 % of the protein, eluted considerably earlier, at -0.6 M-NaCl. The yields from about 5 mg of starting material were 0.9 and 1.2 mg of fractions I and II respectively after concentration of the pools. Antithrombin produced by CHO cells gave a very similar elution pattern and yield.
Fractions I and II from both BHK cells and CHO cells gave one band in SDS/PAGE under reducing conditions (Fig. 2) . Moreover, both fractions from the two cell lines had amino acid compositions similar to that of plasma antithrombin and had the N-terminal sequence His-Gly-Ser-Pro-Val-, identical with that of the plasma inhibitor. Immunodiffusion analyses showed that the two fractions were immunologically identical with each other and with plasma antithrombin. The protein in both fractions I and II was thus essentially homogeneous antithrombin.
Heparin-and thrombin-binding properties of recombinant antithrombin fractions
The difference in heparin affinity between fractions I and II indicated by affinity chromatography was established by fluorescence titrations (Table 1) . High-affinity heparin bound to fraction II from both BHK cells and CHO cells with a dissociation constant of -20 nm, i.e. with an affinity similar to that measured for plasma antithrombin . In contrast, the dissociation constant for the binding of high-affinity heparin to fraction I from both BHK cells and CHO cells was nearly 10-fold higher, i.e. -175 nm. The fluorescence increase at saturation of the protein with high-affinity heparin was similar to that with plasma antithrombin material was not seen on re-chromatography of the fractions on heparin-Sepharose (see Fig. 4 , and increasing concentrations of antithrombin, which were at least 10-fold higher than the thrombin concentration. As derived in the Appendix, the inactivation of thrombin under these conditions is a pseudo-first-order process, with the following dependence of the observed pseudo-first-order rate constant (kobs.) on the heparin and antithrombin concentrations:
where kcat /KT is the specificity constant for thrombin as a substrate for heparin, KATH is the dissociation constant for the binary antithrombin-heparin complex, kuncat is the second-order rate constant for the uncatalysed antithrombin-thrombin reaction, and a subscript zero indicates total concentrations. Rate constants for the inactivation of thrombin at different antithrombin concentrations were obtained from the slopes of semilogarithmic plots of thrombin activity versus time, which all were linear and showed no indications of lags, and were plotted against the concentration of the inhibitor (Fig. 3) Table 3 . Relative proportions of different N-linked oligosaccharides and average degree of sialylation of these oligosaccharides from fractions I and II of recombinant antithrombin from BHK and CHO cells Analyses were done by HPAE-PAD after the oligosaccharides had been released from the pooled glycopeptides and digested with neuraminidase, as described in the Materials and methods section. The proportions of the different oligosaccharides are expressed as percentages of the total amount of oligosaccharides recovered, as calculated from the peak areas of the chromatograms. Similarly, the average degree of sialylation is expressed as the amount of NeuAc obtained from the chromatograms as a percentage of the total amount of oligosaccharides recovered. diffuse than that obtained with plasma antithrombin (Fig. 2) , consistent with a greater size heterogeneity of the two recombinant fractions. Moreover, in all experiments, fraction I reproducibly migrated more slowly than fraction II (Fig. 2) , indicative of a slightly higher Mr. To clarify the structural background for this apparent molecular size difference, we digested the two fractions with a mixture of endoglycosidase F and N-glycosidase F, known to remove N-linked (but not 0-linked) carbohydrate side chains from glycoproteins (Elder & Alexander, 1982; Plummer et al., 1984; Tarentino et al., 1985; Chu, 1986) . The digestion was done after denaturation of the proteins, which greatly facilitates removal of the side chains by making them more accessible to the glycosidases (Tarentino et al., 1985) . A moderate concentration ofenzyme was sufficient to deglycosylate plasma antithrombin and recombinant antithrombin fractions I and II from BHK cells (Fig. 2) . The digestion markedly decreased the apparent size heterogeneity of the two fractions and also abolished their apparent Mr difference. The two deglycosylated proteins thus migrated in SDS/PAGE under reducing conditions as essentially single sharp bands with no discernible difference in mobility from each other or from the band given by deglycosylated plasma antithrombin (Fig. 2) . The apparent Mr of the digested proteins was -45000, similar to that of unglycosylated recombinant antithrombin produced by CHO cells in the presence of tunicamycin (Zettlmeissl et al., 1989) , and also in approximate agreement with the size of the polypeptide chain of antithrombin (Petersen et al., 1979; Bock et al., 1982) , indicating complete removal of the carbohydrate side chains. The antithrombin fractions from CHO cells were found to be considerably more difficult to deglycosylate than those from BHK cells, as is evident from the only partial deglycosylation occurring under the conditions used for the latter material (Fig. 2) . However, full deglycosylation could be achieved with about 50-fold more enzyme, in agreement with earlier studies on unfractionated recombinant antithrombin from CHO cells (Zettlmeissl et al., 1989 The relative proportions of different N-linked oligosaccharides in fractions I and II and the average degree of sialylation of these oligosaccharides were analysed by HPAE-PAD after release of the oligosaccharides from the total glycopeptide pool, followed by desialylation (Table 3 ). All oligosaccharides recovered were regular biantennary, triantennary and tetra-antennary oligosaccharides, fucosylated at the proximal GlcNAc (Zettlmeissl et al., 1989; . Fraction I from CHO cells contained a higher proportion of tetra-antennary oligosaccharides and a lower proportion of biantennary oligosaccharides than fraction II, in agreement with the differences in glycosylation suggested by the deglycosylation experiments presented above. Fraction I from CHO cells also had a lower content of NeuAc than fraction II, a result that was verified by analyses of NeuAc released by acid hydrolysis from the undigested proteins. However, no corresponding differences in oligosaccharide composition could be ascertained for the two fractions from BHK cells. Analyses of the glycosylation pattern at individual glycosylation sites were not feasible, because of the limited amounts of material available.
Heparin affinity of deglycosylated recombinant antithrombin fractions To investigate whether the decreased heparin affinity of fraction I was due to the different glycosylation pattern of this fraction, we digested fractions I and II, as well as plasma antithrombin, with endoglycosidase F/N-glycosidase F under non-denaturing conditions. These experiments could be done only with the two fractions from BHK cells, since the protein produced by CHO cells was difficult to deglycosylate even under denaturing conditions. SDS/PAGE under reducing conditions showed that 80-90 % of the deglycosylated recombinant fractions and plasma antithrombin migrated as a band of Mr -45000, indicating that most, although not all, of the carbohydrate side Vol. 286 I. Bj6rk and others chains could be removed from the proteins also in their native state (results not shown). This removal resulted in the major part of plasma antithrombin eluting at a higher ionic strength in affinity chromatography on immobilized heparin (Fig. 4) , consistent with earlier observations that one or more carbohydrate chains of the protein interfere with heparin binding (Peterson & Blackburn, 1985; Brennan et al., 1987) . Notably, deglycosylated fraction I eluted at the same position as deglycosylated plasma antithrombin (Fig. 4) . A substantial amount of deglycosylated protein from fraction II also eluted at this position, although a large part of the material eluted at a slightly higher ionic strength (Fig. 4) Trimble & Maley, 1984) , consistent with no such component being detected in the analyses of N-linked oligosaccharides by HPAE-
PAD.
The two fractions of recombinant antithrombin produced by BHK cells were also digested with neuraminidase. The untreated fractions migrated somewhat more slowly towards the anode and showed more bands than plasma antithrombin in PAGE under native conditions, reflecting lower and more heterogeneous sialylation (Zettlmeissl et al., 1989) . Digestion with neuraminidase decreased the mobility of the two fractions appreciably and also caused them to migrate indistinguishably from neuraminidase-treated plasma antithrombin, indicating that all or most of the NeuAc residues were removed by the enzyme from all three proteins (Zettlmeissl et al., 1989) . However, this removal did not alter the elution position of either fraction I or II (nor of plasma antithrombin) in heparin affinity chromatography (results not shown), suggesting that the different heparin affinities of the two fractions are not due to different contents of NeuAc.
DISCUSSION
Previous studies have shown that recombinant antithrombin produced by mammalian cell lines is heterogeneously glycosylated (Zettlmeissl et al., 1987 (Zettlmeissl et al., , 1988 (Zettlmeissl et al., , 1989 . In the present work we provide evidence that this heterogeneity affects the biological properties of the inhibitor. A substantially decreased affinity for heparin of a large proportion of the recombinant antithrombin molecules produced by two different cell lines thus was found to be due to a higher carbohydrate content of these molecules.
Variations in the affinity of antithrombin for matrix-linked heparin, most likely involving differences in glycosylation, have previously been reported for antithrombin expressed in transformed African green monkey kidney (COS) cells (Stephens et al., 1987) and BHK cells (Li, 1991) . A difference in carbohydrate structure affecting biological activity in an analogous manner as for antithrombin has been shown for tissue plasminogen activator, expressed in CHO cells (Spellman et al., 1989) . A fully glycosylated form of this enzyme having three oligosaccharide side chains thus had only about two-thirds of the activity of a form lacking one of these chains (Einarsson et al., 1985) .
Moreover, lowered N-glycosylation of the enzyme following sitespecific mutagenesis of two or three carbohydrate attachment sites resulted in a 2-3-fold increase in specific activity (Zettlmeissl et al., 1991) . Another protein in which decreased glycosylation leads to increased biological activity is erythropoetin, for which removal of one of three oligosaccharide side chains by sitespecific mutagenesis was shown to almost double the activity (Yamaguchi et al., 1991) . In contrast, glycosylation variants of a plasma proteinase inhibitor related to antithrombin, aLproteinase inhibitor, had indistingishable inhibitory activities (Guzdek et al., 1990) , consistent with the observations in the present work that the differences in glycosylation ofantithrombin did not affect the intrinsic rate constant of the uncatalysed or heparin-catalysed inhibition of thrombin. The observation that an increased glycosylation of recombinant antithrombin leads to a decreased affinity for heparin is in agreement with previous work indicating that the carbohydrate side chains of antithrombin affect its heparin-binding properties. A normal variant of antithrombin (antithrombin ,3) found in small amounts in plasma thus has about 3-fold higher heparin affinity than the major fraction of the inhibitor, presumably due to the absence of an oligosaccharide side chain at Asn-135 (Peterson & Blackburn, 1985; Brennan et al., 1987) . When present, this side chain apparently interferes with heparin binding, most likely by steric hindrance (Peterson & Blackburn, 1985) . Repulsion from the negative charge of the NeuAc residues is less probable, in view of the negligible effect of removal of these residues on heparin affinity shown in this work. An effect of carbohydrate side chains on heparin binding is also indicated by the identification of a mutant antithrombin with decreased heparin affinity, in which Ile-7 is replaced by Asn, resulting in an Asn-Cys-Thr glycosylation sequence not present in normal antithrombin (Brennan et al., 1988) . The lower heparin affinity of the mutant inhibitor appears to be at least partly due to the presence of an extra carbohydrate side chain at this site.
The nature of the carbohydrate side chains that cause a decrease in the heparin affinity of a large proportion of the recombinant antithrombin molecules could not be identified in this work, because of the limited amounts of material available. The presence of 0-linked oligosaccharides interfering with heparin binding is unlikely because of the specificity of the enzymes used for deglycosylation and because no 0-glycosylation could previously be demonstrated in either plasma antithrombin or the unfractionated recombinant protein (Franzen et al., 1980; Mizuochi et al., 1980; Zettlmeissl et al., 1989) . Moreover, all classical N-glycosylation sites having the sequence Asn-XaaSer/Thr (Nakai & Kanehisa, 1988) are normally glycosylated in the major fraction of plasma antithrombin with which comparisons were made (Petersen et al., 1979; Bock et al., 1982) , making the presence of an N-linked oligosaccharide at a site not used in the plasma inhibitor also less likely. However, a potential other N-glycosylation site, Asn-Xaa-Cys, which carries carbohydrate side chains in some proteins (Nakai & Kanehisa, 1988), occurs close to the C-terminus in the antithrombin sequence (Petersen et al., 1979; Bock et al., 1982) and may have been glycosylated by the cell lines producing the recombinant proteins. An alternative, and perhaps more likely, explanation is that the carbohydrate side chains at one or more critical, normal, N-glycosylation sites are appreciably larger in the low-affinity recombinant antithrombin fraction than in the high-affinity fraction or the plasma protein. By analogy with previous results, a bulkier than normal oligosaccharide side chain at Asn-135, and probably also at Asn-155 and Asn-192, thus would be expected to decrease the heparin affinity -of the inhibitor (Peterson & Blackburn, 1985; Brennan et al., 1987; Zettlmeissl et al., 1991) . This alternative is supported by the demonstration in the present and previous work (Zettlmeissl et at., 1989 ) that the oligosaccharides of recombinant antithrombin produced by mammalian cells have a considerable proportion of tri-and tetra-antennary chains, fucosylated at the proximal GlcNac, which are not detected in normal plasma antithrombin. This explanation is also in agreement with the finding that the weakly binding fraction produced by CHO cells has a higher overall proportion of tetra-antennary side chains than the more tightly binding fraction. The fact that a corresponding difference in overall oligosaccharide composition could not be demonstrated for the two fractions from BHK cells may be due to the presence of bulky oligosaccharides at sites affecting heparin affinity being compensated by the attachment of smaller chains to other sites in the low-affinity fraction from this cell line. A further possibility for the different heparin affinities of the two fractions consistent with the data is that a site at which glycosylation normally interferes with heparin binding, e.g. Asn-135, is not glycosylated in the fraction with high affinity for heparin. In this case, the presence of bulkier than normal carbohydrate side chains at the other carbohydrate attachment sites of this fraction may account for the protein still having an apparent molecular size and heparin affinity comparable with those of plasma antithrombin. However, glycosylation of all sites with bulky oligosaccharides in the low-affinity fraction presumably leads to a further increase in apparent molecular size and a decrease in heparin affinity.
Our findings that the glycosylation state of recombinant antithrombin affects the heparin affinity of the inhibitor are of particular relevance for studies aimed at characterizing the structure and localization of the heparin-binding site of antithrombin by site-directed mutagenesis. Valid conclusions regarding the effect of a particular amino acid substitution on heparin affinity thus require that wild-type and mutant recombinant proteins with equivalent glycosylation patterns be compared. Alternatively, comparisons of heparin affinity can also be made between fully deglycosylated forms of the proteins.
